MAPT and Alzheimer disease: This study showed that 18F-APN-1607 PET imaging could help to clarify the spatial distribution of tau deposition in AD patients and presented a negative correlation between 18F-APN-1607 uptake in specific brain regions and overall severity of cognitive impairment.